肾康注射液联合包醛氧淀粉治疗慢性肾功能衰竭的观察

张磊

摘要：目的  觀察肾康注射液联合包醛氧淀粉治疗慢性肾功能衰竭的临床疗效。方法  选取2018年6月～2019年6月我院诊治的112例慢性肾功能衰竭患者为研究对象，采用随机数字表法分为对照组和观察组，各56例。对照组采用包醛氧淀粉治疗，观察组在对照组基础上联合肾康注射液治疗，比较两组临床治疗总有效率、治疗前后肾功能指标[24h尿蛋白（24h Pro）、尿素氮（BUN）、血肌酐（Scr）]、治疗后临床症状评分及临床不良反应发生情况。结果  观察组临床治疗总有效率94.64%，高于对照组80.36%，差异有统计学意义（P<0.05）;治疗后两组24h Pro、BUN、Scr均低于治疗前，且观察组低于对照组，差异有统计学意义（P<0.05）;治疗后观察组恶心呕吐、疲乏、浮肿症状评分均低于对照组，差异有统计学意义（P<0.05）;观察组临床不良反应发生率（7.14%）与对照组（8.93%）比较，差异无统计学意义（P>0.05）。结论  慢性肾功能衰竭采用肾康注射液联合包醛氧淀粉治疗疗效确切，有助于缓解临床症状、改善肾功能，且不会增加不良反应，应用安全可靠。

关键词：肾康注射液;包醛氧淀粉;肾功能衰竭

中图分类号：R692.5                                 文献标识码：A                                 DOI：10.3969/j.issn.1006-1959.2020.09.050

文章编号：1006-1959（2020）09-0150-02

Observation on Treatment of Chronic Renal Failure with Shenkang Injection Combined

with Oxyamyli Tectus Aldehydum

ZHANG Lei

（Department of Nephrology，Peoples Hospital of Baodi District，Tianjin 301800，China）

Abstract：Objective  To observe the clinical effect of Shenkang injection combined with oxyamyli tectus aldehydum in the treatment of chronic renal failure.Methods  A total of 112 patients with chronic renal failure diagnosed and treated in our hospital from June 2018 to June 2019 were selected as the research object. They were divided into a control group and an observation group with a random number table method， 56 cases each. The control group was treated with oxyamyli tectus aldehydum.The observation group was treated with Shenkang injection on the basis of the control group. The total clinical treatment efficiency， renal function indexes before and after treatment were compared between the two groups[24h urine protein （24h Pro）， urea nitrogen （BUN），blood creatinine （Scr）]， clinical symptom scores and clinical adverse reactions after treatment.Results  The total effective rate of clinical treatment in the observation group was 94.64%， higher than the control group 80.36%， the difference was statistically significant（P<0.05）; 24h Pro， BUN， and Scr of the two groups after treatment were lower than before treatment， and the observation group was lower than the control The difference between the two groups was statistically significant （P<0.05）; the scores of symptoms of nausea， vomiting， fatigue and edema were lower in the observation group after treatment than the control group，the difference was statistically significant（P<0.05）;Compared with the control group （8.93%）， the incidence of clinical adverse reactions （7.14%） in the observation group was not statistically significant（P>0.05）.Conclusion  The treatment of chronic renal failure with Shenkang injection combined with oxyamyli tectus aldehydum has definite curative effect， which can help relieve clinical symptoms and improve renal function without increasing adverse reactions. It is safe and reliable.